COURTNEY GARZA: Open Payments
NPI 1669980603 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$244 in 14 payments from 8 companies in 2025. Trend: 2023 $107 · 2024 $286 · 2025 $244
Food & beverage: $244
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 4 | $79 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $43 |
| PFIZER INC. | 2 | $32 |
| Novartis Pharmaceuticals Corporation | 2 | $28 |
| AstraZeneca Pharmaceuticals LP | 1 | $17 |
| E.R. Squibb & Sons, L.L.C. | 1 | $17 |
| Merck Sharp & Dohme LLC | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
Products named: AREXVY, ELIQUIS, Kerendia, LEQVIO, SHINGRIX, FARXIGA, VERQUVO, NEXLETOL.
Industry payments across TX — which companies pay providers there.
